Yesterday evening, RxSight released preliminary revenue results ... delay procedures indefinitely by continuing to wear their glasses or contact lenses. However, a softening of the overall premium ...

Presenting today are RxSight President and Chief Executive Officer, Dr. Ron Kurtz; and Chief Financial Officer, Shelley Thunen. Yesterday evening, RxSight released preliminary revenue results for the ...

This story has a lot of personal sentiment and comes from the last words spoken by my brother at the end of 2018, the day he ...

I have confidently helped patients navigate the IOL selection process for both cataract surgery and refractive lens exchange.Like all surgeons, I consider several factors, including patients’ ocular ...

RxSight posted a sequential revenue decline, revealing cracks in momentum despite earlier signs of profitability. Revised 2025 outlook and lack of expected profitability suggest earlier optimism ...

RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The company had revenue of $40.21 million for the quarter, compared to analyst estimates of $40.23 million.

Piper Sandler initiated coverage of RxSight (RXST) with a Neutral rating and $18 price target The firm likes the company’s novel light adjustable lens technology and that it plays in the ...

RxSight (NASDAQ:RXST), a maker of light-adjustable intraocular lenses, fell ~28% in the premarket on Thursday after the company slashed its full-year guidance and announced lower-than-expected ...

RxSight, Inc. (NASDAQ:RXST – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports.

RxSight RXST underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings ...

RxSight, Inc. ALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to ...

RxSight lowered 2025 revenue outlook to $160 million-$175 million, below the $188.9 million estimate. BofA downgrades RxSight to Underperform, citing slowing growth. Price target cut from $36 to $ ...